Medigene's Asian deal helps fund PhIII breast cancer trial with EndoTAG-1
This article was originally published in Scrip
Medigene has struck the first licensing deal for its pipeline candidate for triple-negative breast cancer (TNBC) EndoTAG-1, granting exclusive co-development and commercialisation rights in Asia, Australia and New Zealand to Taiwan's SynCore Biotechnology.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.